Last $7.87 USD
Change Today +0.14 / 1.81%
Volume 895.3K
IMGN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

immunogen inc (IMGN) Snapshot

Open
$7.77
Previous Close
$7.73
Day High
$7.97
Day Low
$7.73
52 Week High
03/6/14 - $17.08
52 Week Low
12/23/14 - $5.34
Market Cap
677.7M
Average Volume 10 Days
872.8K
EPS TTM
$-0.85
Shares Outstanding
86.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMMUNOGEN INC (IMGN)

immunogen inc (IMGN) Related Businessweek News

No Related Businessweek News Found

immunogen inc (IMGN) Details

ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. It develops its products using its antibody-drug conjugates technology. The company offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. Its product candidates include IMGN853, which is in Phase I clinical trials for the treatment of ovarian cancer, endometrial cancer, and other cancers; IMGN289 that is in Phase I clinical trials for treating squamous cell carcinoma of head and neck cancer, and non-small cell lung cancer; IMGN529, which is in Phase I clinical trials for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia; and IMGN779 that is in preclinical stage for treating acute myeloid leukemia. The company also develops compounds, such as AMG 172 that is in Phase I clinical trials for the treatment of clear cell renal cell carcinoma; AMG 595, which is in Phase I clinical trials for treating glioblastoma; BAY 94-9343 is in early clinical trials for the treatment of mesothelioma and ovarian cancer; BT-062 for multiple myeloma; SAR3419, which has completed Phase II clinical trials for the treatment of diffuse large B-cell lymphoma; SAR650984 that is in early clinical trials for the treatment of multiple myeloma; SAR566658 that is in Phase I clinical trials for treating CA6-positive solid tumors; and SAR408701 for solid tumors. It has collaborations with Amgen Inc.; Bayer HealthCare; Biotest AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; the Roche Group; and Sanofi. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.

307 Employees
Last Reported Date: 08/28/14
Founded in 1981

immunogen inc (IMGN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $544.5K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $245.0K
Chief Development Officer and Executive Vice ...
Total Annual Compensation: $432.4K
Executive Vice President of Distinguished Res...
Total Annual Compensation: $377.2K
Compensation as of Fiscal Year 2014.

immunogen inc (IMGN) Key Developments

ImmunoGen, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 08:30 AM

ImmunoGen, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 08:30 AM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Daniel M. Junius, Chief Executive Officer, President and Director.

ImmunoGen, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended December 31, 2014; Reaffirms Earnings Guidance for the Full Year of Fiscal 2015

ImmunoGen, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended December 31, 2014. For the quarter, total revenues were $48,300,000 against $30,060,000 a year ago. Income from operations was $13,781,000 against $3,751,000 a year ago. Net income was $13,635,000 against $3,813,000 a year ago. Basic and diluted net income per common share was $0.16 against $0.04 a year ago. Capital expenditures were $2.6 million in the second quarter, which was consistent with $2.3 million in the same quarter last year. The company reported second quarter adjusted EPS of $0.16, up from $0.04. For the six months, total revenues were $61,503,000 against $47,278,000 a year ago. Income from operations was $8,129,000 against $7,586,000 a year ago. Net loss was $8,647,000 against net income of $7,414,000 a year ago. Basic and diluted net loss per common share was $0.10 against $0.09 a year ago. Cash used in operations was $34.4 million compared to $21.6 million in the same period last year, reflecting increased investment in advancing wholly owned programs. The company reaffirmed earnings guidance for the full year of fiscal 2015, its revenues to be between $100 million and $105 million; its net loss to be between $60 million and $65 million; its cash used in operations to be between $55 million and $60 million; and its capital expenditures to be between $7 million and $9 million.

ImmunoGen, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 08:30 AM

ImmunoGen, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 08:30 AM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Daniel M. Junius, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMGN:US $7.87 USD +0.14

IMGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €9.75 EUR +0.201
Abzena PLC 82.00 GBp 0.00
BioInvent International AB kr2.42 SEK +0.03
Genmab A/S kr546.50 DKK +25.50
MorphoSys AG €74.50 EUR +1.05
View Industry Companies
 

Industry Analysis

IMGN

Industry Average

Valuation IMGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.0x
Price/Book 8.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOGEN INC, please visit www.immunogen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.